Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.

"Declaration of Competing Interest F.S.O., J.G.P., M.P., M.R.W., J.K., and L.M.S. are listed as inventors on a pending patent application describing SARS-CoV-2 human mNAbs."

"We want to thank BEI Resources for providing the SARS-CoV-2 USA-WA1/2020 isolate (NR-52281). We want to thank Dr. Thomas Moran (Center for Therapeutic Antibody Development at The Icahn School of Medicine at Mount Sinai) for providing us with the anti-SARS NP 1C7 and the S 2B4E10 mouse mAbs. We would like to thank members at our institutes for their efforts in keeping them fully operational during the COVID-19 pandemic and the IBC committee for reviewing our protocols in a time efficient manner. We would like to dedicate this manuscript to all COVID-19 victims and to all heroes battling this disease. Research in LMS laboratory was partially funded by the New York Influenza Center of Excellence (NYICE), a member of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract No. HHSN272201400005C (NYICE)."